Drugs Made In America Acquisition Corp. Reports Q2 2026 Financial Results and Merger Plans

Drugs Made In America Acquisition Corp. reported its financial results for the second quarter of 2026, revealing a net income of $1.73 million for the three months ending June 30, 2026, compared to $2.29 million for the same period in 2025. For the first half of 2026, the company recorded a net income of $3.70 million, slightly up from $3.54 million in the prior year. The income primarily stemmed from interest earned on cash and investments held in the trust account, which amounted to $1.86 million and $3.98 million for the respective periods. General and administrative costs were reported at $136,934 for the second quarter and $280,235 for the first half of 2026, reflecting a decrease from $131,919 and $462,844 in the same periods of 2025.

The company experienced significant changes in its balance sheet compared to the previous fiscal period. As of June 30, 2026, total assets were reported at $146.9 million, a decrease from $239.9 million at the end of 2025. This decline was largely due to a reduction in cash and investments held in the trust account, which fell from $239.9 million to $146.8 million. The number of ordinary shares subject to possible redemption also decreased from 23 million to approximately 13.6 million, following a redemption of shares by shareholders amounting to $99.3 million.

Strategically, the company is in the process of finalizing a merger agreement with PAGC, which is expected to enhance its operational capabilities and market presence. The merger is intended to position the combined entity as a publicly traded company on The Nasdaq Stock Market. Additionally, the company has extended its business combination period to April 29, 2027, allowing for further time to identify and finalize a target business. This extension was made possible through deposits made by BV Advisory Partners, LLC, totaling $600,000.

Operationally, the company reported a total of 24,276,913 ordinary shares outstanding as of June 30, 2026. The company has not yet commenced any operations and does not expect to generate revenue until after the completion of its initial business combination. The management has indicated that it will continue to incur significant costs in pursuit of its acquisition plans, raising concerns about its ability to continue as a going concern without successfully completing a business combination.

Looking ahead, the company remains focused on identifying a suitable target in the pharmaceutical industry, leveraging the funds held in the trust account for its business combination. However, management has acknowledged the uncertainty surrounding its ability to raise capital or complete a business combination within the extended timeframe, emphasizing the need for strategic execution in the coming months.